Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 20/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196676 | 0.95 | FASN (0.55) | FASN | |
| SCHEMBL4208088 | 0.93 | FASN (0.55) | FASN | |
| SCHEMBL14162163 | 0.92 | FASN (0.49) | FASN | |
| SCHEMBL4196574 | 0.88 | FASN (0.59) | FASN | |
| SCHEMBL4199015 | 0.88 | FASN (0.62) | FASN | |
| SCHEMBL4787007 | 0.87 | FASN (0.53) | FASN | |
| SCHEMBL4782375 | 0.87 | FASN (0.46) | FASN | |
| SCHEMBL4202327 | 0.86 | FASN (0.63) | FASN | |
| SCHEMBL4201403 | 0.86 | FASN (0.65) | FASN | |
| SCHEMBL4199020 | 0.86 | FASN (0.64) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2008075064-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | FASN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.